succinic acid mono-{2-[4-(2,4-dioxo-thiazolidin-5-ylmethyl)-phenoxymethyl]-2,5,7,8-tetramethyl-chroman-6-yl} ester

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: succinic acid mono-{2-[4-(2,4-dioxo-thiazolidin-5-ylmethyl)-phenoxymethyl]-2,5,7,8-tetramethyl-chroman-6-yl} ester
• 英文别名: 2-[4-(2,4-Dioxothiazolidin-5-ylmethyl)phenoxymethyl]-2,5,7,8-tetramethylchroman-6-yl hydrogen succinate；4-[[2-[[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]methyl]-2,5,7,8-tetramethyl-3,4-dihydrochromen-6-yl]oxy]-4-oxobutanoic acid
• 化学式: C₂₈H₃₁NO₈S
• 分子量: 541.622
• InChiKey: ZFKRHQZBTDTJNE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  38
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  154
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  carbonic acid tert-butyl ester 2-{4-[2,4-dioxothiazolidin-5-ylmethyl]phenoxymethyl}-2,5,7,8-tetramethylchroman-6-yl ester 在 盐酸 、 4-二甲氨基吡啶 、 水 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 48.75h， 生成 succinic acid mono-{2-[4-(2,4-dioxo-thiazolidin-5-ylmethyl)-phenoxymethyl]-2,5,7,8-tetramethyl-chroman-6-yl} ester
  参考文献：
  名称：

  新曲格列酮衍生物的合成：在乳腺癌细胞系中的抗增殖活性和初步毒理学研究

  摘要：

  乳腺癌是女性中最普遍的癌症。对治疗剂的抗药性的发展以及对三阴性乳腺癌的靶向治疗的缺乏促使人们寻求替代疗法。出于这个目标，我们合成了曲格列酮的新衍生物，曲格列酮是以前用作抗糖尿病药并且对多种癌细胞系均具有抗增殖活性的化合物。在制备的化合物中，一些化合物对激素依赖性和激素依赖性乳腺癌细胞表现出微摩尔活性。此外，评估了化合物对人肝细胞原代培养物活力的影响。这使我们首次获得了该化合物家族中有趣的结构-毒性关系，得到6b和8b，与曲格列酮相比，显示出良好的抗增殖活性和对肝细胞的不良毒性。

  DOI：

  10.1016/j.ejmech.2012.02.044

文献信息

• Thiazolidine derivatives, their preparation and use
  申请人：Sankyo Company, Limited

  公开号：US05104888A1

  公开（公告）日：1992-04-14

  Compounds of formula (I): ##STR1## (in which R.sup.1 -R.sup.7 are hydrogen or various organic groups, n is 1-10, Ar is an aromatic group, U is CH.sub.2 or a carbon atom doubly bonded to either one of its adjacent carbons, and W is >CH.sub.2, >C.dbd.O, >CHOH, >C.dbd.NOH or various derivatives thereof) have the ability to lower the levels of blood lipid peroxides and blood sugars and to inhibit the activity of aldose reductase; they may be used therapeutically for these purposes.

  公式(I)的化合物：##STR1##（其中R.sup.1 -R.sup.7是氢或各种有机基团，n是1-10，Ar是芳香族基团，U是CH.sub.2或一个碳原子与任一相邻的碳原子双键连接，W是>CH.sub.2，>C.dbd.O，>CHOH，>C.dbd.NOH或其各种衍生物）具有降低血脂过氧化物和血糖水平以及抑制醛糖还原酶活性的能力；它们可以用于这些目的的治疗。
• Monoclonal antibodies as surrogate receptors in a high throughput screen for compounds that enhance insulin sensitivity
  作者：Stuart W. Bright、Gerald Gold、Scott W. Sage、J.Richard Sportsman、Frank C. Tinsley、Samuel J. Dominianni、Klaus K. Schmiegel、Marcia L. Kellam、Lora L. Fitch、Terence T. Yen

  DOI：10.1016/s0024-3205(97)00934-x

  日期：1997.10

  Monoclonal antibodies (MoAbs) were made to a known insulin sensitivity enhancer (ISE) compound, CS-045. The MoAbs were characterized with respect to binding other known thiazolidinedione ISE compounds using a CS-045 labeled with b-phycoerythrin in a competitive particle concentration fluorescence immunoassay (PCFIA). By comparing the rank order of IC50 values for each compound to its respective potency as an ISE, one MoAb (13E3) was selected for further characterization. This MoAb was also used as a surrogate receptor in a high throughput screen to identify novel compounds that compete for binding to CS-045. Some of the hits were found to have efficacy in reducing blood glucose. Subsequently, another group reported that several compounds with the core thiazolidinedione structure of the ISE compounds bound with high affinity to peroxisome proliferator-activating receptors (PPAR). Therefore, we used the MoAb assay to test these and other compounds that are known to bind to PPAR gamma and noted crossreactivity with some of the compounds.
• US5104888A
  申请人：——

  公开号：US5104888A

  公开（公告）日：1992-04-14